TKI-3

"TKI-3" is a study-specific placeholder designation for one of five FDA-approved tyrosine kinase inhibitors (TKIs) evaluated in research conducted by Taichung Veterans General Hospital and National Chung Hsing University (presented at SNO 2025). The study investigated the potential of these clinically approved TKIs to enhance the expansion and anti-tumor cytotoxicity of human gamma-delta (γδ) T cells, specifically the Vγ9Vδ2 subset, for the treatment of glioblastoma multiforme (GBM). While the research identified "TKI-1" (likely dasatinib) as a potent enhancer of γδ T cell activity and cytotoxic markers, "TKI-3" represents another agent in the screening panel—likely a standard TKI such as imatinib, nilotinib, bosutinib, or ponatinib—that was tested but did not demonstrate the same level of immunostimulatory efficacy in this specific adoptive cell therapy model.